LLY vs NVO: which stock is the better buy?
Eli Lilly and Company and Novo Nordisk A/S, graded by the same fixed-weight model from live fundamentals — composite score, 12-month forecast, valuation, growth and margins, side by side. As of July 6, 2026.
On today’s numbers, Eli Lilly and Company grades higher — 70/100 vs 65/100. Tap either card for the full factor breakdown.
Metric by metric
| Metric | LLY | NVO |
|---|---|---|
| TradersQuant Score | 70/100 ✓ | 65/100 |
| Price | $1,210.50 | $50.43 |
| 12-mo base forecast | $1,791.89 | $46.61 |
| Implied upside | +48.0% ✓ | -7.6% |
| Bull / bear range | $1,975.82 / $1,736.87 | $53.60 / $43.99 |
| P/E | 42.9 | 11.8 ✓ |
| Forward P/E | — | — |
| Revenue growth (YoY) | +44.7% ✓ | +6.4% |
| Gross margin | 83.5% ✓ | 81.8% |
| Market cap | $1.14T | $224.1B |
| Sector | Healthcare | Healthcare |
✓ marks the stronger reading per metric (lower is better for P/E). Figures refresh continuously; research, not financial advice.
Want the full verdict on LLY and NVO?
The AI bull/base/bear thesis, smart-money positioning, options signals and insider activity on both — every systematic call graded in public against the S&P 500.
$0 today · cancel before day 7 and you won’t be charged
LLY vs NVO — FAQ (2026)
Is LLY or NVO the better buy right now?
On the live TradersQuant composite score, Eli Lilly and Company (LLY) currently grades higher at 70/100 versus 65/100 for NVO. The score weighs valuation, growth, earnings quality, momentum, the macro regime, sentiment and balance-sheet risk — open each stock's page for the full breakdown. Research, not financial advice.
Which has more 12-month upside, LLY or NVO?
TradersQuant's 12-month base-case forecast currently implies +48.0% for LLY and -7.6% for NVO. Both forecasts are three-scenario models (bull/base/bear) refreshed continuously and graded on our public track record.
How is this LLY vs NVO comparison calculated?
Both stocks are scored by the same fixed-weight model — 20% valuation, 20% growth, 15% earnings quality, 15% momentum, 10% macro regime fit, 10% analyst sentiment, 10% balance-sheet risk — from live fundamentals and prices. No hand-picking: the same arithmetic runs on every stock we cover, and our systematic calls are graded in public against the S&P 500.